Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/175616
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Centa, Ariana | - |
dc.contributor.author | Rodriguez Barrueco, Ruth | - |
dc.contributor.author | Montero, Juan Carlos | - |
dc.contributor.author | Pandiella, Atanasio | - |
dc.date.accessioned | 2021-03-23T10:45:29Z | - |
dc.date.available | 2021-03-23T10:45:29Z | - |
dc.date.issued | 2018-06-01 | - |
dc.identifier.issn | 1574-7891 | - |
dc.identifier.uri | http://hdl.handle.net/2445/175616 | - |
dc.description.abstract | The neuregulins (NRGs) represent a large family of membrane-anchored growth factors, whose deregulation may contribute to the pathogenesis of several tumors. In fact, targeting of NRG-activated pathways has demonstrated clinical benefit. To improve the efficacy of anti-NRG therapies, it is essential to gain insights into the regions of NRGs that favor their pro-oncogenic properties. Here, we have addressed the protumorigenic impact of different NRG domains. To do this, deletion mutants affecting different NRG domains were expressed in 293 and MCF7 cells. Of the five forms studied, only the wild-type and a mutant lacking the Ig-like domain (NRGΔIg ) were properly sorted to the plasma membrane. Both forms were released as soluble forms to the culture media. However, the mutant NRGΔIg failed to efficiently activate HER2 and HER3 receptors, signaling pathways, and cell proliferation when compared to wild-type NRG. Treatment with trastuzumab, a humanized antibody used in the breast cancer clinic, inhibited the constitutive activation of HER2, HER3, and downstream signaling in MCF7 cells constitutively expressing wild-type NRG. In contrast, this treatment had a marginal effect on MCF7-NRGΔIg cells. This study demonstrates that the Ig-like region of NRGs exerts an important role in their capability to activate ErbB/HER receptors and mitogenic responses. Strategies aimed at targeting NRGs should consider that fact to improve neutralization of the pro-oncogenic properties of NRGs. | - |
dc.format.extent | 16 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1002/1878-0261.12310 | - |
dc.relation.ispartof | Molecular Oncology, 2018, vol. 12, num. 7, p. 1061-1076 | - |
dc.relation.uri | https://doi.org/10.1002/1878-0261.12310 | - |
dc.rights | cc-by (c) Centa, Ariana et al., 2018 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Immunoglobulines | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Proliferació cel·lular | - |
dc.subject.other | Immunoglobulins | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Cell proliferation | - |
dc.title | The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 694318 | - |
dc.date.updated | 2021-03-23T10:45:29Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 29683256 | - |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
694318.pdf | 1.75 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License